Valproate Versus Ketorolac Versus Metoclopramide

Status Completed

Clinical Trial Summary

This randomized study is testing 3 different intravenous medications to see which one is best for acute migraine. The three medications are metoclopramide, valproate, and ketorolac.

Clinical Trial Description

One million patients present to US emergency departments (ED) annually for treatment of acute migraine headache. A variety of parenteral medications are used to treat acute migraine, but none offer rapid and complete headache relief without side effects. Preliminary studies have suggested that intravenous valproate, an anti-epileptic medication with established efficacy as a migraine preventive, may be useful for the treatment of acute migraine. We propose a randomized, comparative efficacy trial in which intravenous valproate is compared to two standard parenteral therapies for acute migraine. There will not be a placebo control. Included subjects will be adults 64 years and younger who meet International Headache Society criteria for acute migraine, who do not have clinical evidence of secondary (organic) headache, and who do not have allergy or contra-indication to the investigational medications. The investigational medications are 1gm of valproate, 10mg of metoclopramide, and 30mg of ketorolac. Patients will be approached for participation and randomized at the time of presentation to the ED. Pain will be assessed on an 11 point (0 to 10) verbal pain scale, validated for use in acute pain trials. Medication will be infused as a slow intravenous drip. The primary outcome will be an improvement in headache intensity one hour after initiation of the intravenous drip. Secondary outcomes include assessments of pain, functional disability, adverse events, and satisfaction with the investigational medication one, two and 24 hours after initiation of the intravenous drip. The primary analysis will use a Student's t-test for independent samples and involve three pair-wise comparisons. Using an alpha of .017 (to account for the three pairwise comparisons), a standard beta, and a validated minimum clinically significant difference on the verbal pain scale, we calculated the need for 330 subjects. An interim analysis will be conducted to determine lack of efficacy of valproate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01267864
Study type	Interventional
Source	Montefiore Medical Center
Contact
Status	Completed
Phase	Phase 4
Start date	November 2010
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04153409` - A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine	Phase 2
Completed	`NCT02279082` - DFN-02 Open Label Safety Study in Patients With Acute Migraine	Phase 3
Completed	`NCT04574362` - Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine	Phase 3
Completed	`NCT01973205` - Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine	Phase 3
Terminated	`NCT04089761` - Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents	N/A
Completed	`NCT03631550` - The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine	N/A
Completed	`NCT05371652` - A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants	Phase 3
Completed	`NCT04218162` - Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean	Phase 3
Completed	`NCT01730326` - Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack	Phase 4
Completed	`NCT04408794` - Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine	Phase 2/Phase 3
Completed	`NCT02745392` - Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine	Phase 2/Phase 3
Completed	`NCT00894556` - A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)	Phase 3
Terminated	`NCT02185703` - Chordate System S020 Acute Migraine Clinical Investigation	N/A
Terminated	`NCT01680029` - PBASE-system Acute Migraine Clinical Investigation	N/A
Completed	`NCT01358279` - Transcranial Direct Current Stimulation for Migraine Attack	N/A
Not yet recruiting	`NCT01228552` - The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine	Phase 3
Completed	`NCT02684409` - Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine	Phase 1
Completed	`NCT02439320` - Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:	Phase 3
Terminated	`NCT01112553` - Treximet Migraine Brain Imaging Research Study	N/A
Completed	`NCT01276977` - Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.